Pharmacogenomics & Personalized Therapeutics
Session Overview
Pharmacogenomics stands at the practical intersection of genomics and clinical medicine, offering a powerful strategy to optimize drug therapy by tailoring it to an individual’s genetic makeup. This session explores the translation of genetic knowledge into actionable prescribing decisions to enhance drug efficacy and minimize adverse effects. We will examine the complete pipeline from gene variant discovery and interpretation to the development of clinical guidelines, their integration into healthcare systems, and the broader ethical and economic considerations of making personalized prescribing a routine standard of care.
Why This Session Matters Now
The evidence base supporting pharmacogenomic interventions is robust and growing, with guidelines now available for numerous drug-gene pairs. However, widespread clinical implementation remains a significant challenge. This session addresses the critical gap between knowledge and practice by focusing on the systems, tools, and frameworks necessary to embed pharmacogenomics into diverse clinical workflows. As pre-emptive genotyping becomes more feasible, understanding how to use this data effectively and ethically is paramount for clinicians, health systems, and policymakers.
Key Scientific and Clinical Themes
Key pharmacogenomic genes and variant interpretation
Establishing the foundational knowledge of high-impact genes (e.g., CYP2D6, CYP2C19, TPMT, DPYD) and the complexities of translating diplotypes into clear phenotypic predictions for clinical use.
Regulatory biomarkers and clinical guidelines
Reviewing the development, validation, and endorsement of pharmacogenomic biomarkers by regulatory agencies and professional societies, and their codification into evidence-based clinical prescribing guidelines.
Specialty-specific pharmacogenomic applications
Exploring the implementation of pharmacogenomics within distinct medical specialties such as psychiatry, cardiology, oncology, and pain management, addressing unique drug profiles and clinical decision contexts.
Health informatics integration and clinical decision support
Focusing on the technological architectures required to deliver genetic data to the point of care, including electronic health record integration, interoperable data standards, and the design of effective clinical decision support alerts.
Health economics and implementation science
Evaluating the cost-effectiveness, cost-benefit, and return on investment of pharmacogenomic testing programs, alongside the study of strategies to overcome barriers to adoption in real-world healthcare settings.
Direct-to-consumer and ethical considerations
Discussing the landscape of consumer-accessible pharmacogenomic testing, including issues of test quality, clinical utility, privacy, data ownership, and the ethical responsibilities in reporting results directly to individuals.
Emerging biomarkers and advanced prediction models
Investigating novel genetic and multi-omic biomarkers beyond classic pharmacokinetic genes, and the development of polygenic risk scores and machine learning models to predict drug response with greater precision.
Nature of Research in This Field
Research in pharmacogenomics is inherently translational and multidisciplinary. It spans from basic biochemical studies of gene function and drug metabolism to large-scale clinical outcome studies, health services research, and informatics development. The field is characterized by strong collaborations between clinical pharmacologists, geneticists, bioinformaticians, health economists, and implementation scientists. A major focus is on generating the real-world evidence and practical implementation tools needed to move pharmacogenomics from a specialized service to a scalable, routine component of clinical practice.
Who Should Attend
This session is designed for:
- Clinical pharmacologists, pharmacists, and prescribing physicians across all specialties.
- Clinical geneticists and molecular pathologists.
- Health informaticians and clinical decision support specialists.
- Healthcare administrators and policy makers.
- Researchers in translational pharmacology and implementation science.
- Professionals from the pharmaceutical and diagnostic industries.
- Bioethicists and legal experts in genomic medicine.
Session Perspective
“Pharmacogenomics & Personalized Therapeutics” is dedicated to the principle that the right dose of the right drug for the right patient is a measurable, achievable goal. This session emphasizes that achieving this goal requires a harmonized ecosystem of robust science, clear guidelines, enabling technology, and thoughtful policy. By examining the full spectrum from gene discovery to bedside application, this forum provides essential insights into the frameworks necessary for the effective and ethical integration of pharmacogenomics into healthcare, transforming prescription from a trial-and-error process into a precisely informed clinical action.
If your research aligns with this session, we invite you to submit an abstract for consideration.
